The Role of EGFR Family Inhibitors in Muscle Invasive Bladder Cancer: A Review of Clinical Data and Molecular Evidence

Journal of Urology

Volumn 193, Issue 1, 2015, Pages 19-29

  Mooso, Benjamin A ^a   Vinall, Ruth L ^d   Mudryj, Maria ^a,b   Yap, Stanley A ^a,c   deVere White, Ralph W ^c   Ghosh, Paramita M ^a,b,c  

^a VA NORTHERN CALIFORNIA HEALTH CARE SYSTEM   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d California Northstate College of Pharmacy   (United States)

Author keywords

antineoplastic agents; drug resistance; EGFR tyrosine kinase inhibitor 324674; neoplasm invasiveness; urinary bladder neoplasms

Indexed keywords

ANTINEOPLASTIC AGENT; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIDERMAL GROWTH FACTOR RECEPTOR 3; EPIDERMAL GROWTH FACTOR RECEPTOR 4; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR;

CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER RECURRENCE; CLINICAL TRIAL (TOPIC); DRUG EFFICACY; HUMAN; MEDLINE; MUSCLE INVASIVE BLADDER CANCER; NEOADJUVANT THERAPY; PRIMARY TUMOR; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; SYSTEMATIC REVIEW; ANTAGONISTS AND INHIBITORS; PATHOLOGY; SIGNAL TRANSDUCTION; SMOOTH MUSCLE; TUMOR INVASION; URINARY BLADDER NEOPLASMS;

ERBB RECEPTORS; HUMANS; MUSCLE, SMOOTH; NEOPLASM INVASIVENESS; SIGNAL TRANSDUCTION; URINARY BLADDER NEOPLASMS;

EID: 85027951236     PISSN: 00225347     EISSN: 15273792     Source Type: Journal    
DOI: 10.1016/j.juro.2014.07.121     Document Type: Review

References (50)

1. Vishnu, P., Mathew, J., Tan, W.W., Current therapeutic strategies for invasive and metastatic bladder cancer. Oncol Targets Ther, 4, 2011, 97.
2. Amsellem-Ouazana, D., Bièche, I., Tozlu, S., et al. Gene expression profiling of ERBB receptors and ligands in human transitional cell carcinoma of the bladder. J Urol, 175, 2006, 1127.
3. Brincks, E.L., Risk, M.C., Griffith, T.S., PMN and anti-tumor immunity—the case of bladder cancer immunotherapy. Semin Cancer Biol, 23, 2013, 183.
4. Böhle, A., Jocham, D., Bock, P.R., Intravesical bacillus Calmette-Guerin versus mitomycin C for superficial bladder cancer: a formal meta-analysis of comparative studies on recurrence and toxicity. J Urol, 169, 2003, 90.
5. Han, R.F., Pan, J.G., Can intravesical bacillus Calmette-Guérin reduce recurrence in patients with superficial bladder cancer? A meta-analysis of randomized trials. Urology, 67, 2006, 1216.
6. Winquist, E., Kirchner, T.S., Segal, R., et al. Neoadjuvant chemotherapy for transitional cell carcinoma of the bladder: a systematic review and meta-analysis. J Urol, 171, 2004, 561.
7. Grossman, H.B., Natale, R.B., Tangen, C.M., et al. Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer. N Engl J Med, 349, 2003, 859.
8. Zachos, I., Konstantinopoulos, P.A., Tzortzis, V., et al. Systemic therapy of metastatic bladder cancer in the molecular era: current status and future promise. Expert Opin Investig Drugs, 19, 2010, 875.
9. Witjes, J.A., Compérat, E., Cowan, N.C., et al. EAU guidelines on muscle-invasive and metastatic bladder cancer: summary of the 2013 guidelines. Eur Urol, 65, 2014, 778.
10. Bindels, E.M., van der Kwast, T.H., Izadifar, V., et al. Functions of epidermal growth factor-like growth factors during human urothelial reepithelialization in vitro and the role of erbB2. Urol Res, 30, 2002, 240.
11. Adam, R.M., Danciu, T., McLellan, D.L., et al. A nuclear form of the heparin-binding epidermal growth factor-like growth factor precursor is a feature of aggressive transitional cell carcinoma. Cancer Res, 63, 2003, 484.
12. Olayioye, M.A., Neve, R.M., Lane, H.A., et al. The ErbB signaling network: receptor heterodimerization in development and cancer. EMBO J, 19, 2000, 3159.
13. Jathal, M.K., Chen, L., Mudryj, M., et al. Targeting ErbB3: the new RTK(id) on the prostate cancer block. Immunol Endocr Metab Agents Med Chem, 11, 2011, 131.
14. Yarden, Y., Sliwkowski, M.X., Untangling the ErbB signalling network. Nat Rev Mol Cell Biol, 2, 2001, 127.
15. Cancer Genome Atlas Research Network. Comprehensive molecular characterization of urothelial bladder carcinoma. Nature, 507, 2014, 315.
16. Messing, E., Gee, J.R., Saltzstein, D.R., et al. A phase 2 cancer chemoprevention biomarker trial of isoflavone G-2535 (genistein) in presurgical bladder cancer patients. Cancer Prev Res (Phila), 5, 2012, 621.
17. Chaux, A., Cohen, J.S., Schultz, L., et al. High epidermal growth factor receptor immunohistochemical expression in urothelial carcinoma of the bladder is not associated with EGFR mutations in exons 19 and 21: a study using formalin-fixed, paraffin-embedded archival tissues. Hum Pathol, 43, 2012, 1590.
18. Chow, N.H., Chan, S.H., Tzai, T.S., et al. Expression profiles of ErbB family receptors and prognosis in primary transitional cell carcinoma of the urinary bladder. Clin Cancer Res, 7, 2001, 1957.
19. Chow, N.H., Liu, H.S., Yang, H.B., et al. Expression patterns of erbB receptor family in normal urothelium and transitional cell carcinoma. An immunohistochemical study. Virchows Arch, 430, 1997, 461.
20. Kramer, C., Klasmeyer, K., Bojar, H., et al. Heparin-binding epidermal growth factor-like growth factor isoforms and epidermal growth factor receptor/ErbB1 expression in bladder cancer and their relation to clinical outcome. Cancer, 109, 2007, 2016.
21. Blaveri, E., Simko, J.P., Korkola, J.E., et al. Bladder cancer outcome and subtype classification by gene expression. Clin Cancer Res, 11, 2005, 4044.
22. Dyrskjøt, L., Kruhøffer, M., Thykjaer, T., et al. Gene expression in the urinary bladder: a common carcinoma in situ gene expression signature exists disregarding histopathological classification. Cancer Res, 64, 2004, 4040.
23. Lee, J.S., Leem, J.S., Lee, S.Y., et al. Expression signature of E2F1 and its associated genes predict superficial to invasive progression of bladder tumors. J Clin Oncol, 28, 2010, 2660.
24. Modlich, O., Prisack, H.B., Pitschke, G., et al. Identifying superficial, muscle-invasive, and metastasizing transitional cell carcinoma of the bladder: use of cDNA array analysis of gene expression profiles. Clin Cancer Res, 10, 2004, 3410.
25. Sanchez-Carbayo, M., Socci, N.D., Lozano, J., et al. Defining molecular profiles of poor outcome in patients with invasive bladder cancer using oligonucleotide microarrays. J Clin Oncol, 24, 2006, 778.
26. National Cancer Institute: The Cancer Genome Atlas Data Portal. Available at http://tcga-data.nci.nih.gov/tcga/. Accessed July 17, 2014.
27. Blehm, K.N., Spiess, P.E., Bondaruk, J.E., et al. Mutations within the kinase domain and truncations of the epidermal growth factor receptor are rare events in bladder cancer: implications for therapy. Clin Cancer Res, 12, 2006, 4671.
28. Alexander, R.E., Montironi, R., Lopez-Beltran, A., et al. EGFR alterations and EML4-ALK rearrangement in primary adenocarcinoma of the urinary bladder. Mod Pathol, 27, 2014, 107.
29. Flaig, T.W., Su, L.J., McCoach, C., et al. Dual epidermal growth factor receptor and vascular endothelial growth factor receptor inhibition with vandetanib sensitizes bladder cancer cells to cisplatin in a dose- and sequence-dependent manner. BJU Int, 103, 2009, 1729.
30. Hovey, R.M., Chu, L., Balazs, M., et al. Genetic alterations in primary bladder cancers and their metastases. Cancer Res, 58, 1998, 3555.
31. Majumdar, S., Gong, E.M., Di Vizio, D., et al. Loss of Sh3gl2/endophilin A1 is a common event in urothelial carcinoma that promotes malignant behavior. Neoplasia, 15, 2013, 749.
32. Røtterud, R., Nesland, J.M., Berner, A., et al. Expression of the epidermal growth factor receptor family in normal and malignant urothelium. BJU Int, 95, 2005, 1344.
33. Tsai, Y.S., Tzai, T.S., Chow, N.H., et al. Frequency and clinicopathologic correlates of ErbB1, ErbB2, and ErbB3 immunoreactivity in urothelial tumors of upper urinary tract. Urology, 66, 2005, 1197.
34. Junttila, T.T., Laato, M., Vahlberg, T., et al. Identification of patients with transitional cell carcinoma of the bladder overexpressing ErbB2, ErbB3, or specific ErbB4 isoforms: real-time reverse transcription-PCR analysis in estimation of ErbB receptor status from cancer patients. Clin Cancer Res, 9, 2003, 5346.
35. Kokai, Y., Myers, J.N., Wada, T., et al. Synergistic interaction of p185c-neu and the EGF receptor leads to transformation of rodent fibroblasts. Cell, 58, 1989, 287.
36. Fleischmann, A., Rotzer, D., Seiler, R., et al. Her2 amplification is significantly more frequent in lymph node metastases from urothelial bladder cancer than in the primary tumours. Eur Urol, 60, 2011, 350.
37. Sergina, N.V., Rausch, M., Wang, D., et al. Escape from HER-family tyrosine kinase inhibitor therapy by the kinase-inactive HER3. Nature, 445, 2007, 437.
38. Junttila, T.T., Sundvall, M., Määttä, J.A., et al. Erbb4 and its isoforms: selective regulation of growth factor responses by naturally occurring receptor variants. Trends Cardiovasc Med, 10, 2000, 304.
39. Muraoka-Cook, R.S., Feng, S.M., Strunk, K.E., et al. ErbB4/HER4: role in mammary gland development, differentiation and growth inhibition. J Mammary Gland Biol Neoplasia, 13, 2008, 235.
40. Jones, F.E., Golding, J.P., Gassmann, M., ErbB4 signaling during breast and neural development: novel genetic models reveal unique ErbB4 activities. Cell Cycle, 2, 2003, 555.
41. Soule, H.D., Vazguez, J., Long, A., et al. A human cell line from a pleural effusion derived from a breast carcinoma. J Natl Cancer Inst, 51, 1973, 1409.
42. Wu, H.C., Hsieh, J.T., Gleave, M.E., et al. Derivation of androgen-independent human LNCaP prostatic cancer cell sublines: role of bone stromal cells. Int J Cancer, 57, 1994, 406.
43. Ni, C.Y., Murphy, M.P., Golde, T.E., et al. gamma-Secretase cleavage and nuclear localization of ErbB-4 receptor tyrosine kinase. Science, 294, 2001, 2179.
44. Schwänhausser, B., Busse, D., Li, N., et al. Global quantification of mammalian gene expression control. Nature, 473, 2011, 337.
45. Pruthi, R.S., Nielsen, M., Heathcote, S., et al. A phase II trial of neoadjuvant erlotinib in patients with muscle-invasive bladder cancer undergoing radical cystectomy: clinical and pathological results. BJU Int, 106, 2010, 349.
46. Petrylak, D.P., Tangen, C.M., Van Veldhuizen, P.J. Jr., et al. Results of the Southwest Oncology Group phase II evaluation (study S0031) of ZD1839 for advanced transitional cell carcinoma of the urothelium. BJU Int, 105, 2010, 317.
47. Philips, G.K., Halabi, S., Sanford, B.L., et al. A phase II trial of cisplatin (C), gemcitabine (G) and gefitinib for advanced urothelial tract carcinoma: results of Cancer and Leukemia Group B (CALGB) 90102. Ann Oncol, 20, 2009, 1074.
48. Hussain, M.H., MacVicar, G.R., Petrylak, D.P., et al. Trastuzumab, paclitaxel, carboplatin, and gemcitabine in advanced human epidermal growth factor receptor-2/neu-positive urothelial carcinoma: results of a multicenter phase II National Cancer Institute trial. J Clin Oncol, 25, 2007, 2218.
49. Wülfing, C., Machiels, J.P., Richel, D.J., et al. A single-arm, multicenter, open-label phase 2 study of lapatinib as the second-line treatment of patients with locally advanced or metastatic transitional cell carcinoma. Cancer, 115, 2009, 2881.
50. Quesnelle, K.M., Grandis, J.R., Dual kinase inhibition of EGFR and HER2 overcomes resistance to cetuximab in a novel in vivo model of acquired cetuximab resistance. Clin Cancer Res, 17, 2011, 5935.